Literature DB >> 3549177

Adult respiratory distress syndrome related to antilymphocyte globulin therapy.

N C Dean, W C Amend, M A Matthay.   

Abstract

A 21-year-old man developed the adult respiratory distress syndrome (ARDS) within five hours of receiving antilymphocyte globulin. No other identifiable cause of ARDS was present. The mechanism for development of acute lung injury is unknown, but may be related either to direct lung cytotoxicity or to complement-mediated leukocyte and platelet destruction with secondary lung injury from inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3549177     DOI: 10.1378/chest.91.4.619

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

Review 1.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

2.  Acute lung injury during antithymocyte globulin therapy for aplastic anemia.

Authors:  Ewan Christopher Goligher; Christine Cserti-Gazdewich; Meyer Balter; Vikas Gupta; Joseph E Brandwein
Journal:  Can Respir J       Date:  2009 Mar-Apr       Impact factor: 2.409

3.  Rapid progression of fibrosing alveolitis and thyrotoxicosis after antithymocyte globulin therapy for aplastic anemia.

Authors:  A Zomas; J C Marsh; N K Harrison; S L Hyer; S S Nussey; G Knee; A G Wilson; A Lakhani; E C Gordon-Smith
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

4.  Anti-thymocyte globulin induced non-cardiogenic pulmonary edema during renal transplantation.

Authors:  Beena K Parikh; Guruprasad P Bhosale; Veena R Shah
Journal:  Indian J Crit Care Med       Date:  2011-10

5.  An avoidable cause of thymoglobulin anaphylaxis.

Authors:  S Brabant; A Facon; F Provôt; M Labalette; B Wallaert; C Chenivesse
Journal:  Allergy Asthma Clin Immunol       Date:  2017-02-23       Impact factor: 3.406

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.